Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

A recent academic case study, published on April 22, examined using Amgen Inc’s AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with…

Related Keywords

,Amgen Inc ,Cullinan Therapeutics Inc ,Cullinan Therapeutics ,Cullinan Oncology ,News ,Ggregator ,Reaking News ,Uration ,Media ,